News and Trends 25 Jul 2022 Bavarian Nordic gets European monkeypox approval for smallpox vaccine Danish company Bavarian Nordic A/S says the European Commission (EC) has extended the marketing authorization for the company’s smallpox vaccine, IMVANEX, to include protection from monkeypox and disease caused by vaccinia virus. The approval, which follows a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) on July 22, 2022, is valid […] July 25, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2022 Drug for acute treatment of social anxiety disorder did not meet primary endpoint A nasal spray to treat anxiety did not meet its primary endpoint and was not significantly better than the placebo given during a phase 3 clinical trial. Vistagen Therapeutics Inc’s drug, PH94B, was designed to treat people living with anxiety, depression and other central nervous system (CNS) disorders announced the topline results on Friday (July […] July 25, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2022 NEOsphere Biotechnologies closes financing round NEOsphere Biotechnologies GmbH has completed a series A financing round to expand its proteomics platform, which screens extensive small-molecule libraries for degraders of pathogenic proteins previously considered undruggable. The funding amount was not disclosed, however, the company told us there were four investors, with the main amount coming from Munich-based Ventura BioMed Investors GmbH. NEOSphere […] July 25, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2022 Macao university research finds mRNA vaccine booster offers more protection against Omicron variants A study in Macao has found people taking the BioNTech mRNA vaccine as the third booster dose produce more neutralizing antibodies against Omicron variants. The study, led by Daniel Baptista-Hon, assistant professor at the Faculty of Medicine at the Macau University of Science and Technology (M.U.S.T.), and Ligong Lu, director of Zhuhai People’s Hospital, was […] July 25, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2022 Replay launches with $55M to reprogram biology by writing and delivering big DNA Replay, a genome writing company reprogramming biology by writing and delivering big DNA, has launched with $55 million in seed financing. The round was led by KKR and OMX Ventures, with additional participation from ARTIS Ventures and Lansdowne Partners, SALT, DeciBio Ventures, and Axial. Replay, which is based in San Diego, Cal., and London, U.K., […] July 25, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Opinion 25 Jul 2022 How to improve patient recruitment in your precision medicine research Precision medicine research relies on genetic testing at scale, but has long suffered recruitment and retention headaches. The answer, says Patrick Short, CEO of Sano Genetics, is to start early and engage participants deeply. I witnessed first-hand the power of national scale genomics research through my PhD work analyzing genome sequence data from more than […] July 25, 2022 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jul 2022 Positive news for Aurinia’s voclosporin drug Lupkynis to treat lupus nephritis British Columbia-based Aurinia Pharmaceuticals Inc. announced today (July 22) that its voclosporin drug has been recommended for marketing authorization to treat adults with active lupus nephritis (LN). The Canadian biopharma company said it is committed to delivering therapeutics that change the course of autoimmune disease after the Committee for Medicinal Products for Human Use (CHMP) […] July 22, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jul 2022 People with hemophilia B could be protected from bleeding by a single dose of a drug currently being trialed London-based Freeline Therapeutics Holdings plc has just announced that positive data on treating haemophilia has been published by the New England Journal of Medicine (NEJM). This expands upon previous data for up to three-and-a-half years from the phase 1/2 dose-finding B-AMAZE of the company’s AAVS3 gene therapy candidate, FLT180a for people with the debilitating, hereditary […] July 22, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jul 2022 InterVenn expands globally to drive the potential of glycoproteomics to improve patient outcomes Intervenn Biosciences is expanding across Asia-Pacific and North America and opening new facilities in Kuala Lumpur, the Philippines, Australia and California. The company leverages glycoporteomics and says it is adding a large footprint of laboratories and office space for scaling up Intervenn’s software development, technical support, clinical research and business development. Biomedical hubs Aldo Carrascoso, […] July 22, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
In Depth 22 Jul 2022 The coming of age story of RNAi technology The first RNA interference (RNAi) therapy was approved in 2018, after 20 years in development. What can we expect to see in the RNAi field in the future? After two decades of scientific effort, multiple devastating clinical trial setbacks, and billions of dollars spent on research and development, RNAi therapies are finally establishing themselves in […] July 22, 2022 - 7 minutesmins - By Farhan Mitha Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jul 2022 Australia looks to biotech alliance The Australian government’s Defence department has announced the launch of the Safeguarding Australia through Biotechnology Response and Engagement alliance (SABRE) at the inaugural Australian Defence Science Technology and Research Summit (ADSTAR) The department said SABRE offers opportunities by bringing together different perspectives of biotech from Australia’s universities, research institutes and small medium enterprises (SME) and […] July 22, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jul 2022 Astellas to create new biotech campus in South San Francisco Astellas Pharma Inc. has unveiled plans to create an integrated biotechnology campus in South San Francisco as its West Coast innovation and research center. The new 154,000-square-foot building at 480 Forbes Boulevard will allow for the co-location of several Astellas business units and functions currently located independently throughout the San Francisco area. The new innovation […] July 22, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email